First-line somatostatin analogs (SSAs) provide both antisecretory and antiproliferative effects for SSTR-positive tumors or carcinoid syndrome (12, 37), with emerging utility in indolent pulmonary carcinoids (40). This evidence concerns the gene SST and carcinoid syndrome.